YJ001
/ Zhejiang Yuejia Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
August 18, 2025
MAD Study to Assess the Safety, Tolerability, PKs and Efficacy of YJ001 for Spray Use in Patients With DPNP
(clinicaltrials.gov)
- P1 | N=24 | Recruiting | Sponsor: Zhejiang Hanmai Pharmaceutical Technology Co., Ltd. | Trial completion date: Mar 2025 ➔ Jun 2026 | Trial primary completion date: Mar 2025 ➔ Dec 2025
Trial completion date • Trial primary completion date • Diabetic Neuropathy • Neuralgia • Pain • Peripheral Neuropathic Pain
August 01, 2024
MAD Study to Assess the Safety, Tolerability, PKs and Efficacy of YJ001 for Spray Use in Patients With DPNP
(clinicaltrials.gov)
- P1 | N=24 | Recruiting | Sponsor: Zhejiang Hanmai Pharmaceutical Technology Co., Ltd. | Not yet recruiting ➔ Recruiting
Enrollment open • Diabetic Neuropathy • Neuralgia • Pain • Peripheral Neuropathic Pain
April 11, 2024
Multiple-Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of YJ001 for Spray Use in Patients With Diabetic Peripheral Neuropathic Pain
(clinicaltrials.gov)
- P1 | N=24 | Not yet recruiting | Sponsor: Zhejiang Hanmai Pharmaceutical Technology Co., Ltd.
New P1 trial • Diabetic Neuropathy • Neuralgia • Pain • Peripheral Neuropathic Pain
1 to 3
Of
3
Go to page
1